NanoViricides' NV-387 Shows Promising Results in Combating Influenza A H3N2 in Mice
TL;DR
NV-387 provides significantly greater survival improvement compared to three approved influenza drugs, making it a powerful therapeutic option for treating severe influenza infections.
NV-387 was found effective in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse model, resulting in lower immune system cell infiltration rates.
NV-387 has the potential to address current and emerging viral threats, offering a critical development in the field of antiviral therapies, making it a better place.
NV-387 oral treatment resulted in only about 31% lung infiltration by immune system cells, while intravenous treatment showed an even lower infiltration rate of about 22%.
Found this article helpful?
Share it with your network and spread the knowledge!
NanoViricides CEO Dr. Anil Diwan recently shared encouraging updates about the company's ultra-broad-spectrum antiviral, NV-387, which has demonstrated significant efficacy in a study involving mice lethally infected with Influenza A H3N2. The antiviral treatment was found to notably protect the lungs from damage, a critical factor in severe respiratory viral infections that often lead to hospitalization and fatalities.
In the study, NV-387 was administered both orally and intravenously. Results showed that oral treatment with NV-387 led to approximately 31% lung infiltration by immune system cells, while intravenous treatment resulted in an even lower infiltration rate of about 22%. In stark contrast, untreated infected animals exhibited a high infiltration rate of 68%. These findings underscore the antiviral's capacity to significantly safeguard the lungs of Balb/c mice infected with the Influenza A H3N2 virus. Furthermore, NV-387 treatment resulted in markedly improved survival rates compared to three approved influenza drugs, positioning NV-387 as a potentially powerful therapeutic option for severe influenza and other respiratory viral infections.
NV-387's protective effects extend beyond reducing lung infiltration. The study also found that the antiviral protected the lungs from both viral and immune system damage, indicating a strong antiviral effect. These results come at a critical time, as the threat potential of bird flu H5N1 has significantly increased due to its spread into several mammalian species. While dairy cattle have experienced relatively mild infections, some mammals, particularly farm cats, have succumbed to brain infections caused by the virus. Human infection cases remain limited, with four documented instances; one fatality occurred in Mexico, while the three other cases in the USA have recovered.
The promising findings of NV-387 highlight its urgent and potential impact in addressing both current and emerging viral threats, marking a significant development in the field of antiviral therapies. For more detailed information, you can view the source version on newsdirect.com.
Curated from News Direct
